Becker's Healthcare August 15, 2024
The antiviral drug tecovirimat did not reduce the duration of mpox lesions in a randomized, placebo-controlled trial.
The results were studied among children and adults with mpox in the Democratic Republic of the Congo, according to an Aug. 15 news release from the National Institutes of Health. Detailed results will be released through scientific channels, the NIH said.
...